0941 GMT - News that Roche's tiragolumab drug candidate didn't meet the primary goal of a late-stage clinical trial in lung cancer doesn't come as a surprise for investors, Bryan Garnier says in a note. The Swiss pharmaceutical company released long-awaited data at final analysis for tiragolumab that showed the overall survival goal wasn't met. This was largely anticipated by the market in light of previous data, Bryan Garnier says. Roche had previously pointed at a limited efficacy in terms of progression-free survival and a miss relative to Merck's Keytruda in a separate arm of the same clinical program, the broker says. Shares fall 1%.(adria.calatayud@wsj.com)
(END) Dow Jones Newswires
November 26, 2024 04:41 ET (09:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。